{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:03:43Z","timestamp":1789441423062,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejca.2022.11.010","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T20:46:38Z","timestamp":1668458798000},"page":"124-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors"],"prefix":"10.1016","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-1188","authenticated-orcid":false,"given":"Richard","family":"Riedel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Fassunke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah L.","family":"Tumbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Scheel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Heydt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Hieggelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Heimsoeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Nogova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3164-870X","authenticated-orcid":false,"given":"Sebastian","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Phillip","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieke N.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Eisert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Schaufler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna","family":"Siemanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela A.","family":"Ihle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Wagener-Ryczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9828-4405","authenticated-orcid":false,"given":"Roberta","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pappesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rehker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"J\u00fcrgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Stoelben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bunck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Kobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Merkelbach-Bruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin L.","family":"Sos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2022.11.010_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in lung cancer: will expectations finally be MET?","volume":"12","author":"Drilon","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2022.11.010_bib2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.010_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JTO.0b013e3181913e0e","article-title":"Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers","volume":"4","author":"Onozato","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.010_bib4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours - molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.010_bib5","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2022.11.010_bib6","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.010_bib7","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1158\/1078-0432.CCR-17-3001","article-title":"Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients","volume":"24","author":"Plenker","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.010_bib8","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14\u2013mutated or MET-amplified non\u2013small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.010_bib9","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.11.010_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2019.05.006","article-title":"Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma","volume":"133","author":"Riedel","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.010_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00117","article-title":"Dramatic response to crizotinib in a patient with lung cancer positive for an HLA-DRB1-MET gene fusion","author":"Davies","year":"2017","journal-title":"JCO Precision Oncology"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.010_bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1021\/cb300663j","article-title":"Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features","volume":"8","author":"Fang","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.ejca.2022.11.010_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol Res"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.010_bib14","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jtho.2019.06.023","article-title":"Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro","volume":"14","author":"Fujino","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2022.11.010_bib15","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1158\/1078-0432.CCR-19-3608","article-title":"Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14-mutant NSCLC","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.010_bib16","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1158\/1078-0432.CCR-20-2861","article-title":"MET exon 14-altered lung cancers and MET inhibitor resistance","volume":"27","author":"Guo","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2022.11.010_bib17","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1158\/2159-8290.CD-16-0686","article-title":"Acquired METD1228V mutation and resistance to MET inhibition in lung cancer","volume":"6","author":"Bahcall","year":"2016","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.ejca.2022.11.010_bib18","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.jtho.2016.06.013","article-title":"Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping","volume":"11","author":"Heist","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2022.11.010_bib19","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1158\/1078-0432.CCR-16-3273","article-title":"Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non-small cell lung cancer","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.ejca.2022.11.010_bib20","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1158\/0008-5472.CAN-10-4433","article-title":"A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients","volume":"71","author":"Tiedt","year":"2011","journal-title":"Cancer Res"},{"issue":"21","key":"10.1016\/j.ejca.2022.11.010_bib21","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-17-1192","article-title":"Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models","volume":"23","author":"Engstrom","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.010_bib22","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/j.jtho.2018.08.451","article-title":"MET kinase domain rearrangements (KDRE) in non-small cell lung cancer (NSCLC) identified through comprehensive genomic profiling (CGP)","volume":"13","author":"Schrock","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2022.11.010_bib23","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1039\/C8LC00322J","article-title":"3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade","volume":"18","author":"Aref","year":"2018","journal-title":"Lab Chip"},{"key":"10.1016\/j.ejca.2022.11.010_bib24","article-title":"Characterization of non-small-cell lung cancers with MET exon 14 skipping alterations detected in tissue or liquid: clinicogenomics and real-world treatment patterns","volume":"5","author":"Lee","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.11.010_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.9067","article-title":"Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC)","volume":"34","author":"Schuler","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.010_bib26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-14-0450","article-title":"MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung","volume":"21","author":"Schildhaus","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2022.11.010_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101832","article-title":"SHP2 inhibition influences therapeutic response to tepotinib in tumors with MET alterations","volume":"23","author":"Pudelko","year":"2020","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.010_bib28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jtho.2016.09.119","article-title":"Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping","volume":"12","author":"Ou","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.010_bib29","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.jtho.2017.10.028","article-title":"Osimertinib and cabozantinib combinatorial therapy in an EGFR-mutant lung adenocarcinoma patient with multiple MET secondary-site mutations after resistance to crizotinib","volume":"13","author":"Kang","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.010_bib30","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-18-1640","article-title":"Activation of KRAS mediates resistance to targeted therapy in MET exon 14-mutant non-small cell lung cancer","volume":"25","author":"Suzawa","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:58Z","timestamp":1760733538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922017464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":30,"alternative-id":["S0959804922017464"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.11.010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}